Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90

Biogen completes acquisition of HI-Bio

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study

LG Chem enters Chinese osteoarthritis treatment market

Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China

Abbott and YRGCARE inaugurate new outreach centers in India

Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases

Merck and Orion announce option providing Merck global exclusive rights to Opevesostat

An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer

ONGC to enhance healthcare facilities at Baltal and Chandanwari in J&K

This initiative underscores a steadfast commitment of ONGC to sustainable development and enhanced public health services

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

HCG acquires 51% stake in Mahatma Gandhi Cancer Hospital and Research Institute, Vizag

Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

Pfizer and BioNTech receive Positive CHMP opinion for Omicron JN.1-adapted COVID-19 vaccine in EU

Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission